About Biosynth
Biosynth is a company based in Thal (Switzerland) founded in 1966 was acquired by KKR in November 2021. It operates as a Managed Services and Direct-to-Consumer (D2C). Biosynth has completed 7 acquisitions, including Cambridge Research Biochemicals, Celares and EUCODIS. Biosynth offers products and services including Complex Chemicals, Peptides, and Key Biologics. Biosynth operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Thal, Switzerland
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biosynth Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$545.67 K (USD), Grant
Jun 01, 2021
-
Investors
KKR
& 1 more
-
Employee Count
Not available
-
Investments & Acquisitions
Cambridge Research Biochemicals
& 6 more
-
Acquired by
KKR
(Nov 01, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biosynth
Biosynth offers a comprehensive portfolio of products and services, including Complex Chemicals, Peptides, and Key Biologics.
Complex chemicals are manufactured for research and industry.
Custom peptides are synthesized for various scientific applications.
Biologics are developed for diagnostics and research purposes.
People of Biosynth
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Biosynth
Investors in Biosynth
Biosynth has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include KKR and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Biosynth
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biosynth
Biosynth has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include Cambridge Research Biochemicals, Celares and EUCODIS.
Investment portfolio details for Biosynth
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Drug research, enzyme identification, biocatalysis, and formulation services are provided.
|
Locked | Locked | 2007 | Locked | |
|
Drug delivery systems using PEGylation for biopharmaceuticals are developed.
|
Locked | Locked | 2003 | Locked | |
|
Complete chemical solutions for industries are developed and manufactured.
|
Locked | Locked | 2001 | Locked |
Complete acquisition details for Biosynth
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Biosynth
Detailed financials for Biosynth
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biosynth Comparisons
Peer comparison for Biosynth
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biosynth
Biosynth operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Biosynth
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biosynth
Complete news archive for Biosynth
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biosynth
Biosynth was founded in 1966 and raised its 1st funding round 55 years after it was founded.
Biosynth is headquartered in Thal, Switzerland. It is registered at Thal, St. Gallen, Switzerland.
Matt Gunnison is the current CEO of Biosynth.
Biosynth is involved in the manufacture and supply of high-quality products for the pharmaceutical, life science, and diagnostic sectors. Operations span across complex chemicals, peptides, and key biologics, addressing needs in food, agrochemistry, and cosmetics industries. Facilities are maintained on three continents with a rapid global distribution network. Custom synthesis and manufacturing services are provided, including GMP manufacturing for clinical and research applications. Expertise in carbohydrates, nucleosides, and enzyme substrates is leveraged to support customer projects. Solutions are tailored to remove barriers in critical projects through problem-solving approaches.
Biosynth's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Biosynth offers Complex Chemicals, Peptides, and Key Biologics.
Biosynth has made 7 acquisitions, including Cambridge Research Biochemicals, Celares, and EUCODIS.
Biosynth has 2 investors. Key investors include KKR, and European Union.